title: [Efficacy and tolerability of dapoxetine in the treatment of premature ejaculation].
abstract: OBJECTIVE
  To investigate the efficacy and adverse effects of dapoxetine in the treatment of premature ejaculation.
  
  
  METHODS
  We randomly assigned outpatients with premature ejaculation in the proportion of 2:1 to receive 30 mg dapoxetine on demand (n =78) or 50 mg sertraline qd for one month (n = 39). Follow-up was accomplished in 95 cases, 63 in the dapoxetine group and 32 in the sertraline group. We recorded the intravaginal ejaculatory latency time (IELT), clinical global impression of change (CGIC) score, and adverse reactions of the patients and compared them between the two groups.
  
  
  RESULTS
  IELT was significantly increased in both the dapoxetine (from [0.87 ± 0.31] to [2.84 ± 0.68] min, P < 0.05) and the sertraline group (from [0.84 ± 0.28] to [2.71 ± 0.92] min, P < 0.05) after medication. Based on the CGIC scores in premature ejaculation, the rate of excellence or effectiveness was 36.5% in the dapoxetine and 37. 5% in the sertraline group, and the rate of improvement was 63.5% in the former and 71.9% in the latter. The incidence rates of dizziness, nausea, headache, and diarrhea were slightly higher (P > 0.05) while those of fatigue, somnolence, and dry mouth significantly higher (P < 0.05) in the sertraline than in the dapoxetine group.
  
  
  CONCLUSIONS
  On-demand oral medication of dapoxetine is effective and well-tolerated for the treatment of premature ejaculation.
authors.forename: Lin
authors.initials: L
authors.lastname: Yang
authors.forename: Lei
authors.initials: L
authors.lastname: Luo
authors.forename: Xing-fa
authors.initials: XF
authors.lastname: Chen
authors.forename: Jin-hai
authors.initials: JH
authors.lastname: Fan
authors.forename: Run-ming
authors.initials: RM
authors.lastname: Liu
authors.forename: Xiao-ning
authors.initials: XN
authors.lastname: Wang
authors.forename: Xun-yi
authors.initials: XY
authors.lastname: Nan
authors.forename: Yue
authors.initials: Y
authors.lastname: Zhang
authors.forename: Xiao-feng
authors.initials: XF
authors.lastname: Lin
authors.forename: Ming-zhu
authors.initials: MZ
authors.lastname: Wang
authors.forename: Jun-ping
authors.initials: JP
authors.lastname: Xing
authors.forename: Zhi-shang
authors.initials: ZS
authors.lastname: Yang
authors.forename: Bai-lu
authors.initials: BL
authors.lastname: Jian
authors.forename: Hui
authors.initials: H
authors.lastname: He
authors.forename: Da-peng
authors.initials: DP
authors.lastname: Wu
authors.forename: Da-lin
authors.initials: DL
authors.lastname: He
mesh_terms: D001596:Benzylamines / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004542:Ejaculation / Q000187:drug effects / Q000502:physiology; D006801:Humans; D008297:Male; D009281:Naphthalenes / Q000009:adverse effects / Q000627:therapeutic use*; D010045:Outpatients; D061686:Premature Ejaculation / Q000188:drug therapy*; D011930:Reaction Time / Q000187:drug effects / Q000502:physiology; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D020280:Sertraline / Q000008:administration & dosage* / Q000009:adverse effects; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D001596:Benzylamines; D009281:Naphthalenes; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline; C080598:dapoxetine